[<sup>18</sup>F] Fluciclatide PET as a biomarker of clinical response to combination therapy of pazopanib and paclitaxel in patients with platinum-resistant or platinum-refractory advanced ovarian cancer: Results of a phase Ib study.
Rohini Sharma(Hammersmith Hospital), Eric O. Aboagye(Imperial College London), Edward S. Chambers(Imperial College London), Hani Gabra(Royal Children's Hospital), Pablo Oriol Valls(Imperial College London), Tara Barwick(Imperial College Healthcare NHS Trust), George Tharakan(Imperial College London), Marianna Inglese(Hammersmith Hospital), Amarnath Challapalli(NIHR Bristol Biomedical Research Centre), Jingky Lozano-Kühne(Imperial College London), Michelle Chen(Stanford Medicine), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Tom Cole(NIHR Imperial Biomedical Research Centre), Suraiya Dubash(Royal College of Radiologists)
Cited by 1
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614